Special Issue

Pharmacology of Neuropeptide S Receptor

Message from the Guest Editors

Much research regarding the NPS/NPSR-system has occurred in the area of neuro- and psychobiology. Strong genetic evidence also points to a role of the NPS-system in allergic and inflammatory diseases. Although drugs acting on NPSR1 are still lacking in clinical practice, this receptor continues to be a target of high interest for the understanding and treatment of several conditions, including anxiety and panic disorders, sleep disorders, drug addiction, food intake disorders, pain, cognitive deficit, and Parkinson's disease, as well as allergies and chronic intestinal inflammatory conditions. Authors involved in research on NPS / NPSR1 are invited to submit original and review articles on preclinical as well as clinical studies concerning functional and pathophysiological aspects of the NPS system. Also, studies involving medicinal chemistry and in vitro models are welcome.

Guest Editors

Dr. Chiara Ruzza

Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy

Dr. Rainer K. Reinscheid

Institute of Pharmacology and Toxicology, University Hospital Jena, Friedrich-Schiller-Universität, Jena, Germany

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/61408

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

